ACS Nano
- WEI Y, Zhao M, He T, Chen N, et al
Quantitatively Lighting up the Spatial Organization of CD47/SIRPalpha Immune
Checkpoints on the Cellular Membrane with Single-Molecule Localization
Microscopy.
ACS Nano. 2023;17:21626-21638.
Aktuelle Urol
-
[Not Available].
Aktuelle Urol. 2024;55:18-20.
-
[Not Available].
Aktuelle Urol. 2024;55:22-23.
-
[Not Available].
Aktuelle Urol. 2024;55:24-25.
Ann Oncol
- NECCHI A, Pouessel D, Leibowitz R, Gupta S, et al
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with
FGF/FGFR genomic alterations: final results from FIGHT-201.
Ann Oncol. 2024;35:200-210.
- SONPAVDE GP, Subbiah V
Unlocking precision oncology with FGFR inhibition in urothelial carcinoma.
Ann Oncol. 2024;35:150-153.
Arch Ital Urol Androl
- RAHMAN ZA, Hidayatullah F, Lim J, Hakim L, et al
A systematic review and meta-analysis of intraarterial chemotherapy for non
muscle invasive bladder cancer: Promising alternative therapy in high
tuberculosis burden countries.
Arch Ital Urol Androl. 2024 Feb 16. doi: 10.4081/aiua.2024.12154.
- PRONTERA PP, Prusciano FR, Lattarulo M, Utano E, et al
Quality of bladder cancer treatment information on YouTube: May the user's
profile affect the quality of results?
Arch Ital Urol Androl. 2024 Feb 16. doi: 10.4081/aiua.2024.12179.
Asia Pac J Clin Oncol
- TAN KL, Viswambaram P, McCombie S, Moe A, et al
Fremantle protocol: Multicenter clinical outcomes for a pragmatic protocol for
intravesical bacillus Calmette-Guerin.
Asia Pac J Clin Oncol. 2023;19:697-705.
- PARK K, Lee HJ, Kim TU, Ryu H, et al
Phase II study of neoadjuvant chemotherapy with four cycles of dose-dense MVAC
followed by radical cystectomy in Korean patients with muscle-invasive or locally
advanced urothelial carcinoma of bladder.
Asia Pac J Clin Oncol. 2023;19:739-746.
- GURNEY H, Clay TD, Oliveira N, Wong S, et al
Systemic treatment of advanced and metastatic urothelial cancer: The landscape in
Australia.
Asia Pac J Clin Oncol. 2023;19:585-595.
Asian J Endosc Surg
- SUZUKI A, Ito H, Uemura K, Muraoka K, et al
Surgical proficiency in laparoscopic radical cystectomy with extracorporeal
urinary diversion and its adequacy for the execution of robot-assisted radical
cystectomy with intracorporeal urinary diversion.
Asian J Endosc Surg. 2024;17:e13289.
Biochem Genet
- LI C, Qin W, Hu J, Lin J, et al
A Machine Learning Computational Framework Develops a Multiple Programmed Cell
Death Index for Improving Clinical Outcomes in Bladder Cancer.
Biochem Genet. 2024 Feb 14. doi: 10.1007/s10528-024-10683.
BMC Cancer
- YANG M, Zhang J, Wei D, Yu T, et al
Inflammatory markers predict survival in patients with postoperative urothelial
carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy.
BMC Cancer. 2024;24:196.
- ZHANG J, Yang M, Wei D, Zhang D, et al
The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin
in the treatment of postoperative patients with muscle-invasive upper tract
urothelial carcinoma.
BMC Cancer. 2024;24:202.
BMC Urol
- IBRAHIM M, Rabinowitz J, Hilbert R, Ghose A, et al
The role of URO17(R) in diagnosis and follow up of bladder cancer patients.
BMC Urol. 2024;24:34.
BMJ
- LOPEZ-BELTRAN A, Cookson MS, Guercio BJ, Cheng L, et al
Advances in diagnosis and treatment of bladder cancer.
BMJ. 2024;384:e076743.
Cancer Med
- HUANG SY, Su PJ, Lin CT, Kuo MC, et al
The impact of body mass index on survival endpoints among patients with
metastatic urothelial carcinoma undergoing treatment with immune checkpoint
inhibitors: A real-world multicenter analysis.
Cancer Med. 2024;13:e7008.
Cancer Sci
- TAMURA D, Abe M, Hiraki H, Sasaki N, et al
Postoperative recurrence detection using individualized circulating tumor DNA in
upper tract urothelial carcinoma.
Cancer Sci. 2024;115:529-539.
Cancers (Basel)
- LU Q, Wang J, Tao Y, Zhong J, et al
Small Cajal Body-Specific RNA12 Promotes Carcinogenesis through Modulating
Extracellular Matrix Signaling in Bladder Cancer.
Cancers (Basel). 2024;16:483.
Chem Biol Drug Des
- SU Y, Chen L, Yang J
Network pharmacology and in vitro experiments reveal sophoridine-induced
apoptosis and G(1) phase arrest via ROS-dependent PI3K/Akt/FoxO3a pathway
activation in human bladder cancer cells.
Chem Biol Drug Des. 2024;103:e14476.
Chembiochem
- BRETON-PATIENT C, Billotte S, Duchambon P, Fontaine G, et al
Light-Activatable Photocaged UNC2025 for Triggering TAM Kinase Inhibition in
Bladder Cancer.
Chembiochem. 2024 Feb 16:e202300855. doi: 10.1002/cbic.202300855.
Clin Genitourin Cancer
- CARMONA O, Kleinmann N, Zilberman DE, Dotan ZA, et al
Do Urine Cytology and FISH Analysis Have a Role in the Follow-Up Protocol of
Upper Tract Urothelial Carcinoma?
Clin Genitourin Cancer. 2024;22:98-105.
- KAWADA T, Yanagisawa T, Rajwa P, Motlagh RS, et al
The Prognostic Value of Tumor Infiltrating Lymphocytes After Radical Cystectomy
for Bladder Cancer: A Systematic Review and Meta-Analysis.
Clin Genitourin Cancer. 2024 Jan 17:S1558-7673(24)00009.
- JOYCE DD, Shan Y, Stewart CA, Chamie K, et al
A SEER-Medicare Based Quality Score for Patients With Metastatic Upper Tract
Urothelial Carcinoma.
Clin Genitourin Cancer. 2024;22:14-22.
- MATHAVAN A, Mathavan A, Murillo-Alvarez R, Gera K, et al
Clinical Presentation and Targeted Interventions in Urachal Adenocarcinoma: A
Single-Institution Case Series and Review of Emerging Therapies.
Clin Genitourin Cancer. 2024;22:67-75.
Clin Radiol
- CAO B, Li Q, Xu P, Zhang Y, et al
Vesical Imaging-Reporting and Data System (VI-RADS) as a grouping imaging
biomarker combined with a decision-tree mode to preoperatively predict the
pathological grade of bladder cancer.
Clin Radiol. 2024 Feb 9:S0009-9260(24)00082-5. doi: 10.1016/j.crad.2024.
Clin Transl Oncol
- SOTELO M, Munoz-Unceta N, Matorras A, Jara P, et al
Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from
a single institution.
Clin Transl Oncol. 2024;26:682-688.
Curr Med Chem
- SU Y, Chen L, Yang J
Hesperetin Inhibits Bladder Cancer Cell Proliferation and Promotes Apoptosis and
Cycle Arrest by PI3K/AKT/FoxO3a and ER Stress-mitochondria Pathways.
Curr Med Chem. 2024 Feb 13. doi: 10.2174/0109298673283888231217174702.
Eur J Med Res
- TANG R, Wang H, Liu J, Song L, et al
TFRC, associated with hypoxia and immune, is a prognostic factor and potential
therapeutic target for bladder cancer.
Eur J Med Res. 2024;29:112.
Eur Urol
- SHARIAT SF, Laukhtina E
Re: Gemcitabine and Cisplatin plus Nivolumab as Organ-sparing Treatment for
Muscle-invasive Bladder Cancer: A Phase 2 Trial. Galsky MD, Daneshmand S,
Izadmehr S, et al. Nat Med 2023;29:2825-34.
Eur Urol. 2024 Feb 14:S0302-2838(24)00066-6. doi: 10.1016/j.eururo.2024.
- FENG YN, Xie GY, Xiao L
Re: Petros Grivas, Se Hoon Park, Eric Voog, et al. Avelumab First-line
Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical
Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol
2023;84:95-108.
Eur Urol. 2023;84:e145.
- PEDERSEN GL, Mogensen K, Rosthoj S, Hermann GG, et al
Reply to Deng-Xiong Li, De-Chao Feng, and Shi Deng's Letter to the Editor re:
Gyrithe Lynghoj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthoj,
Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser
Destruction of Blad
Eur Urol. 2023;84:e154.
- LI DX, Feng DC, Deng S
Re: Gyrithe Lynghoj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne
Rosthoj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser
Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic
Diagnosis-gui
Eur Urol. 2023;84:e152-e153.
Expert Rev Anticancer Ther
- FILIPPI L, Schillaci O
NECTIN-4 targeted theranostics for urothelial cancer: getting ready for
primetime?
Expert Rev Anticancer Ther. 2024;24.
Folia Med (Plovdiv)
- SHISHKOV DD, Shishkov DG, Todorov S, Mihaylov N, et al
Laparoscopic vs. open surgical access radical cystectomy with subsequent
orthotopic reconstruction in the treatment of invasive urothelial carcinoma of
the bladder.
Folia Med (Plovdiv). 2023;65:894-901.
Gene
- SILVA IMD, Vacario BGL, Okuyama NCM, Barcelos GRM, et al
Polymorphisms in drug-metabolizing genes and urinary bladder cancer
susceptibility and prognosis: Possible impacts and future management.
Gene. 2024;907:148252.
Heliyon
- PAN G, Xie H, Xia Y
Disulfidptosis characterizes the tumor microenvironment and predicts
immunotherapy sensitivity and prognosis in bladder cancer.
Heliyon. 2024;10:e25573.
Indian J Pathol Microbiol
- CHENNIAPPAN A, Stephen NS, Srinivas BH, Sreenivasan SK, et al
Plasmacytoid urothelial carcinoma with duodenal metastasis-A rare tumor with
unusual site of metastasis with grim outcome.
Indian J Pathol Microbiol. 2024;67:175-177.
- GUPTA RK, Wasnik P, Sharma AR
Papillary urothelial neoplasm of low malignant potential with osseous metaplasia
in a 19-year-old chronic smoker: A case report with review of literature.
Indian J Pathol Microbiol. 2024;67:159-161.
Int J Hyperthermia
- XU Y, Sun G, Yang T, Li H, et al
Validation of hyperthermia as an enhancer of chemotherapeutic efficacy: insights
from a bladder cancer organoid model.
Int J Hyperthermia. 2024;41:2316085.
Int J Mol Sci
- LI AH, Park SY, Li P, Zhou C, et al
Transcriptome Analysis Reveals Anti-Cancer Effects of Isorhapontigenin (ISO) on
Highly Invasive Human T24 Bladder Cancer Cells.
Int J Mol Sci. 2024;25:1783.
- KUSTRIMOVIC N, Bilato G, Mortara L, Baci D, et al
The Urinary Microbiome in Health and Disease: Relevance for Bladder Cancer.
Int J Mol Sci. 2024;25:1732.
- GILL E, Perks CM
Mini-Review: Current Bladder Cancer Treatment-The Need for Improvement.
Int J Mol Sci. 2024;25:1557.
Int J Surg
- WEI Z, Xv Y, Liu H, Li Y, et al
A CT-based deep learning model predicts overall survival in patients with muscle
invasive bladder cancer after radical cystectomy: a multicenter retrospective
cohort study.
Int J Surg. 2024 Feb 13. doi: 10.1097/JS9.0000000000001194.
Int Urol Nephrol
- MOEEN AM, Hameed DA, Mostafa MG, Shaban SH, et al
Lymphadenectomy before and after radical cystectomy: does this affect the
radicality? A prospective randomized comparative study.
Int Urol Nephrol. 2024;56:965-972.
- ZHAI H, Wang Y, Chen Z, Wang Z, et al
Clinicopathological characteristics, surgical treatments, and oncological
outcomes of localized primary unifocal urothelial carcinoma involving the
ureterovesical junction.
Int Urol Nephrol. 2024;56:941-955.
- KOBERLE B, Usanova S, Piee-Staffa A, Heinicke U, et al
Strong apoptotic response of testis tumor cells following cisplatin treatment.
Int Urol Nephrol. 2023 Oct 27. doi: 10.1007/s11255-023-03825.
Integr Cancer Ther
- MAIMON Y, Amiel G, Cohen Z, Hoffman A, et al
Prevention of Bladder Cancer Recurrence With the Botanical Formula LCS103: A Case
Series Study.
Integr Cancer Ther. 2024;23:15347354241233233.
J Clin Med
- FAN LW, Li YR, Wu CM, Chuang KT, et al
Inpatient Outcomes of Patients Undergoing Robot-Assisted versus Laparoscopic
Radical Cystectomy for Bladder Cancer: A National Inpatient Sample Database
Study.
J Clin Med. 2024;13:772.
J Coll Physicians Surg Pak
- CETIN T, Bolat D, Cesur G, Erdemoglu O, et al
Comparison of Monopolar Versus Bipolar Repeat Transurethral Resection of
Bladder Tumours.
J Coll Physicians Surg Pak. 2024;34:230-234.
J Urol
- BOCHNER BH, Kamat AM, Bivalacqua TJ
Open vs Robotic Cystectomy: Case Closed?
J Urol. 2024;211:473-475.
JAMA Oncol
- NECCHI A, Faltas BM, Slovin SF, Meeks JJ, et al
Immunotherapy in the Treatment of Localized Genitourinary Cancers.
JAMA Oncol. 2023;9:1447-1454.
- KATIMS AB, Tallman J, Vertosick E, Porwal S, et al
Response to 2 Induction Courses of Bacillus Calmette-Guerin Therapy Among
Patients With High-Risk Non-Muscle-Invasive Bladder Cancer: 5-year Follow-Up of a
Phase 2 Clinical Trial.
JAMA Oncol. 2024 Feb 15. doi: 10.1001/jamaoncol.2023.6804.
Lakartidningen
- LIEDBERG F, Hagberg O, Aljabery F, Falini V, et al
[Radical cystectomy for bladder cancer is a complex procedure].
Lakartidningen. 2024;121:23132.
Med
- ZHU X, Koshkin VS
Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic
urothelial cancer.
Med. 2024;5:106-108.
- MATHEW THOMAS V, Grivas P, Agarwal N
Gemcitabine with cisplatin and nivolumab: Redefining standard of care for
first-line metastatic urothelial carcinoma?
Med. 2024;5:109-111.
Mol Cancer
- XIE T, Peng S, Liu S, Zheng M, et al
Multi-cohort validation of Ascore: an anoikis-based prognostic signature for
predicting disease progression and immunotherapy response in bladder cancer.
Mol Cancer. 2024;23:30.
Mol Oncol
- RAC G, Patel HD, James C, Desai S, et al
Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence
and identifies responders to intravesical therapy.
Mol Oncol. 2024;18:291-304.
Nat Commun
- AMARA CS, Kami Reddy KR, Yuntao Y, Chan YS, et al
The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in
SMARCB1-deficient bladder cancer.
Nat Commun. 2024;15:1373.
- RIJNDERS M, Nakauma-Gonzalez JA, Robbrecht DGJ, Gil-Jimenez A, et al
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response
to immune checkpoint inhibitors in urothelial cancer.
Nat Commun. 2024;15:1349.
Neuropathol Appl Neurobiol
- TAUZIEDE-ESPARIAT A, Masliah-Planchon J, Tran S, Filser M, et al
Brain metastasis of a urothelial neuroendocrine carcinoma: A double pitfall for
neuropathologists and DNA-methylation profiling.
Neuropathol Appl Neurobiol. 2024;50:e12951.
Pathol Res Pract
- NGUYEN NJ, Sherman C, van der Kwast TH, Downes MR, et al
Aggressive prostatic adenocarcinoma with urothelial-like morphology, with
frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features:
A clinicopathologic study of 12 cases.
Pathol Res Pract. 2024;254:155105.
Pharm Biol
- LUO S, Huang X, Li S, Chen Y, et al
Homogeneous Polyporus polysaccharide exerts anti-bladder cancer effects via
autophagy induction.
Pharm Biol. 2024;62:214-221.
Radiat Oncol
- ALI M, Koo K, Chang D, Chan P, et al
Low rate of severe-end-stage kidney disease after SABR for localised primary
kidney cancer.
Radiat Oncol. 2024;19:23.
Sci Rep
- LEE CU, Lee JH, Lee HW, Chung JH, et al
Analysis of progression after elective distal ureterectomy and effects of salvage
radical nephroureterectomy in patients with distal ureteral urothelial carcinoma.
Sci Rep. 2024;14:3497.
Transl Res
- LI M, Yan X, Liu H, Miao W, et al
Novel MSH2 and TSC2 variants in a Chinese family with Lynch syndrome and their
synergistic impact in urothelial carcinoma.
Transl Res. 2024;265:26-35.
Urol Oncol
- YILMAZ H, Teke K, Suer E, Izol V, et al
Does neo-adjuvant chemotherapy improve the negative effect of lymphovascular
invasion in survival after radical cystectomy?
Urol Oncol. 2024;42:30.
- LUO S, Wu Y, Yang R, Huang G, et al
Intra-arterial chemotherapy plus BCG, a promising combination adjuvant treatment
for high-risk NMIBC.
Urol Oncol. 2024;42:30.
- GWAK CH, Suh J, Lim B, Song C, et al
Preoperative C-reactive protein to albumin ratio as a novel prognostic biomarker
for the oncological outcomes of radical nephroureterectomy.
Urol Oncol. 2024;42:30.
- KARAHAN I, Bilgin B
Is my patient with urothelial cancer (in)eligible for platinum?
Urol Oncol. 2024;42:27.
Urologie
- VOS N, Minner J, Bohm J
[Paraganglioma of the urinary bladder-a rare, but relevant differential
diagnosis].
Urologie. 2024;63:168-170.
World J Urol
- ORTNER G, Guven S, Somani BK, Nicklas A, et al
Experts' recommendations in laser use for the treatment of bladder cancer: a
comprehensive guide by the European Section of Uro-Technology (ESUT) and Training
and Research in Urological Surgery and Technology (TRUST)-Group.
World J Urol. 2024;42:79.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016